A&O recruits five-strong Goodwin team, launches in Boston
Allen & Overy has hired five partners from Goodwin Procter to boost its US life sciences litigation practice.
AstraZeneca sues Taro in blood-thinning drug patent dispute
AstraZeneca has sued Taro Pharmaceuticals in two US federal courts alleging that Taro’s planned generic blood-thinning treatment infringes a patent for its Brilinta (ticagrelor) medication.
Otsuka says Teva’s REXULTI generic infringes patents
Otsuka Pharmaceutical has sued Teva Pharmaceuticals, alleging that the company’s planned generic of Otsuka’s REXULTI antipsychotic (brexpiprazole) tablets infringe five of its patents.
Canada delivers landmark ruling in favour of big pharma
The Quebec Court of Appeal in Canada has ruled that the 2019 amendments to the Patented Medicines Regulations, governing the country’s Patented Medicine Prices Review Board (PMPRB) are partially invalid.
Janssen seeks to halt generic schizophrenia drug
Johnson & Johnson unit Janssen Pharmaceuticals has filed a suit against Intas Pharmaceuticals, seeking to block the India-based drugmaker from launching a generic version of schizophrenia drug Invega Sustenna (paliperidone palmitate).
Warren calls for government to seize Pfizer patents
US Senator Elizabeth Warren has urged the Department of Health and Human Services (HHS) to seize control of patents covering Pfizer’s prostate cancer drug Xtandi (enzalutamide).
Pfizer sues Teva over arthritis treatment
Pfizer has sued Teva Pharmaceuticals, alleging that the Israeli pharma company is planning on releasing a generic of Pfizer’s Xeljanz XR arthritis treatment before the branded drug’s key patent expires.
Roche and AstraZeneca units settle blood drug suit
Roche’s Chugai and AstraZeneca’s Alexion Pharmaceuticals have brought their patent infringement dispute over a treatment for rare, fatal blood diseases to an end.
Judge partially revives California pay-for-delay ban
A Californian judge has partially revived the state’s pay-for-delay ban after attorney general Rob Bonta requested that a preliminary injunction against the ban be modified.
Afrigen creates COVID vaccine using Moderna data
Afrigen Biologics has used the publicly available information relating to Moderna’s COVID-19 vaccine to manufacture its own version of the treatment, which could see testing by the end of this year.
